In this series, we will talk about the natural history of variceal bleeding, current standard of care, patients defined as high risk for treatment failure,…

You may have noticed that we often start antibiotics for patients with cirrhosis to prevent spontaneous bacterial peritonitis (SBP). Have you ever wondered why?

Lactulose and Rifaximin (Xifaxan) are standards of care for the prevention of overt hepatic encephalopathy in patients with cirrhosis. Have you ever wondered why? Join…

In a follow-up to an outstanding overview of NSBB therapy in liver disease, Part 2 of this series by Anahita Rabiee presents evidence in support of earlier use of NSBBs in cirrhosis. Read on!

In the first post from new LFN author Anahita Rabiee, we are gifted an authoritative review on the Whys and Hows of beta-blockade in decompensated cirrhosis! You definitely want to read this one!

In a very special installment of the Why Series, our adult and pediatric teams join forces to answer the question of how living donor liver transplantation came about in the United States. Read on!

In part 2 of our coagulopathy series, we take a deeper dive and learn the ways in which end-stage liver disease alters the body’s normal hemostatic mechanisms.

Patients with end-stage liver disease have elevated INRs. They bleed frequently and they clot perhaps more frequently. Do they need FFP before a paracentesis? What’s a TEG? These questions answered, and more, in our multi-part series on the coagulopathy of liver disease!

In Part 1 of this series, we reviewed what came BEFORE the MELD score—Child-Turcotte-Pugh classification. We additionally discussed the history behind MELD, what is included in its calculation and why, and how it is used in transplant listing. Is everyone excited for Part 2?

The Model for End-stage Liver Disease (or MELD) score is used to determine patient priority for liver transplantation. But have you ever wondered why? Let us review the history and the literature to better understand why this score is so meaningful!